Distributor of medical devices, disposable medical devices, and scientific devices
| 6M25 | 6M24 | 2024 | 2023 |
|---|
| Revenues | 251.91 | 201.16 | 447.40 | 394.41 |
| Expenses | 213.07 | 174.27 | 378.77 | 363.63 |
| Net Profit (Loss) | 30.09 | 19.96 | 53.42 | 21.87 |
| Assets | 487.68 | 316.08 | 461.10 | 302.43 |
| Liabilities | 196.29 | 216.89 | 179.41 | 223.20 |
| Shareholders' Equity | 291.39 | 99.19 | 281.70 | 79.23 |
| Operating | 70.39 | 7.50 | 53.24 | -15.52 |
| Investing | -5.82 | -6.96 | -10.19 | -8.75 |
| Financing | -23.27 | 3.84 | 122.67 | -1.77 |
| EPS (Baht) | 0.18 | 0.17 | 0.40 | 0.20 |
| GP Margin (%) | 32.79 | 32.99 | 35.06 | 29.55 |
| NP Margin (%) | 11.94 | 9.92 | 11.94 | 5.55 |
| D/E Ratio (x) | 0.67 | 2.19 | 0.64 | 2.82 |
| ROE (%) | 32.54 | 31.24 | 29.60 | 27.60 |
| ROA (%) | 20.05 | 13.42 | 17.98 | 10.18 |
SEI Medical Public Company Limited is implementing a plan to consistently expand its product range. This expansion will concentrate on high-quality medical devices and healthcare products that utilize advanced technology, aiming to meet future market needs.. This product expansion will cover both the consumer and medical sectors, creating new revenue sources and growing the customer base in both public and private markets.
The company is also working to broaden its business model to offer a full range of services. This includes strong after-sales support and comprehensive assistance for client businesses, ensuring customers can effectively use the company's products and services. For instance, SEI Medical will offer leasing of the latest medical equipment.
Additionally, SEI Medical is seeking opportunities to establish joint ventures with companies in the medical industry. These partnerships will strengthen the company's business and open new markets. These joint ventures will enhance competitiveness, expand market reach, and develop products that meet the needs of rapidly growing customer market to meet the needs of customers in a rapidly growing market.
The company is focused on expanding its product range, particularly in the consumable goods sector, which is consistently purchased and not dependent on annual government budgets. This product category is critical for hygiene and aligns with future market trends. Expanding this product range will allow the company to generate stable and sustainable revenue by addressing the growing demand in the healthcare sector.
Moreover, the company’s product leasing service is another key strategy for ensuring business sustainability. This approach not only helps reduce the initial investment burden for customers but also enables them to continuously upgrade medical equipment to stay current with advancements. Additionally, leasing helps reduce maintenance responsibilities and enhances operational flexibility, which aligns with current trends in cost management and operational efficiency for organizations.
In the second quarter of 2025, the Company demonstrated its potential to generate consistent revenue, with total revenue for the six-month period showing continuous growth compared to 2024. The Company recorded total sales of THB 224.33 million, representing an increase of 23.46% compared to total sales of THB 181.71 million in the second quarter of 2024.
The main drivers of this growth stem from the company's on-schedule delivery of goods across all product categories, including the addition of new product lines in the medical equipment category for Intensive Care Units (ICU Care), resulting in increased total sales.
The Company has implemented an efficient cost management policy, enabling it to consistently maintain an appropriate gross profit margin. In addition, the Company places great emphasis on inventory management by keeping inventory levels aligned with market demand, while closely monitoring inventory turnover to prevent excessive accumulation. This approach reduces the risk of obsolete stock and supports the efficient utilization of resources.
Based on this operational success, the company has demonstrated its ability to adapt and continuously improve operational efficiency, which serves as a crucial foundation for sustainable growth in the future.
In the first half of 2025, SEI Medical Public Company Limited achieved strong and stable growth by utilizing public funding to expand its product line for Intensive Care Units (ICU) and enhance its service department. This is a key part of the company's strategy for comprehensive growth, both vertically and horizontally.
The company's performance in the service sector has been particularly outstanding. While the target for full-year growth was set at a minimum of 30%, the service department's growth in the second quarter reached an impressive 45.36%. This significantly exceeded the set goal, reflecting strong market demand and the success of the company's service upgrades.
SEI Medical plans to continue expanding and building on its service business, including maintenance and training for medical personnel. This will help generate stable revenue from services related to sales and drive the company's long-term, sustainable growth.
The company has implemented a plan to diversify its product offerings, particularly in consumables that are not dependent on annual government budgets, to ensure business sustainability and reduce risks associated with changes in government policies that may impact the business in the long term.
Furthermore, the company has increased investments in other business areas, such as after-sales services, equipment leasing, and expanding its customer base in the private sector. This will help generate diverse revenue streams and strengthen financial stability in the long term. These measures will enable the company to better manage market volatility and reduce the risks associated with reliance on a single revenue source.
| as of 30/06/25 | SEI | CONSUMP | mai |
|---|---|---|---|
| P/E (X) | 6.78 | 24.23 | 60.02 |
| P/BV (X) | 1.59 | 0.99 | 1.15 |
| Dividend yield (%) | 4.23 | 4.48 | 3.94 |
| 30/06/25 | 30/12/24 | - | |
|---|---|---|---|
| Market Cap (MB) | 482.80 | 676.60 | N/A |
| Price (B/Share) | 2.84 | 3.98 | N/A |
| P/E (X) | 6.78 | 17.08 | N/A |
| P/BV (X) | 1.59 | 2.52 | N/A |